ACTRN12618000761268招募中2 期
A 56 week, Double-Blind, Randomised Study to Evaluate the Efficacy of Testosterone, With and without DHA Supplementation on Cerebral Amyloid Load in Men with Subjective Memory Complaints
Australian Alzheimer's Research Foundation Inc0 个研究点目标入组 120 人开始时间: 2018年5月7日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 60 Years 至 80 Years（—）
- 性别
- Male
入选标准
- •1. Men aged 60 – 80 years at the time of signing the consent
- •2. Able to personally read and understand the Participant Information and Consent Form and provide written, signed and dated informed consent to participate in the study
- •3. Able and willing to meet all protocol-required procedures and visits
- •4. Must have an available project partner who has sufficient contact (at least 5 hours per week) with the participant to provide reliable information on the cognitive and functional abilities of the participant
- •5. Must have Global PiB-like SUVR score of 1.3 - 2.0 on PET (completed within 12 months of Day 1)
- •6. A MoCA score of 23 to 30 at the Screening Visit dependant on age and education, see appendix III
- •7. A score of greater than or equal to 25 on Memory Complaints Questionnaire (MAC-Q) at Screening Visit
- •8. General cognition and functional performance are preserved to the extent that that no suspected or possible Mild Cognitive Impairment or AD with dementia exists based on the results of neuropsychological testing at Screening IV. Note: If a comparable neuropsychological battery (as determined by the lead neuropsychologist) has been performed
- •within 4 months of screening, the data collected can be used to assess this criterion.
- •9. Visual and auditory acuity to perform the cognitive tests (eyeglasses and hearing aids permitted)
- •10. Be willing to provide a blood sample for Apolipoprotein E (APOE) genotyping
排除标准
- •1. Pathological androgen deficiency (< 8 nmol/L) in accordance with current Pharmaceutical Benefits Scheme guidelines requiring testosterone replacement, or testosterone supplementation during the previous 2 years
- •2. Serum testosterone measurement greater than or equal to 18 nmol/L within 6 months of study or at the Screening Visit
- •3. Use of any medication known to:
- •Affect testosterone or SHBG within the previous 1 month or with an underlying condition where there is any possibility that permanent usage may be required within the next 12 months
- •Affect the production (e.g. opiates, GnRH agonists) or action (e.g. spironolactone) of androgens
- •Affect the production [e.g. opiates, GnRH agonists] or action [e.g. spironolactone, Duodart (combination of Tamsulosin and Dutasteride), Avodart (Dutasteride)] of androgens
- •4. Known to have hypothalamo-pituitary or significant testis pathology (excl. cryptorchidism)
- •5. Known clinically significant folic acid or B12 deficiency
- •6. Diagnosed with severe untreated Obstructive Sleep Apnoea (OSA) or commenced CPAP within the previous 6 months
- •7. Type 1 diabetes mellitus
- •8. Clinically significant systemic illness or serious infection (e.g., pneumonia, septicemia) within 30 days prior to or during Screening
- •9. Known to be Human Immunodeficiency Virus (HIV) positive
- •10. Participants should not be included in the study if they are taking chronic narcotic analgesic treatment (including codeine), anti-psychotics, tricyclic antidepressants, dopamine agonists, benzodiazepines, lithium, oral corticosteroids*, other anti-cholinergics, cholinesterase inhibitors, paroxetine [an SSRI that is anticholinergic] – If any of these drugs are taken intermittently (no more than three times a week) there should be no use within 2 days of any cognitive testing *In the case of low dose corticosteroids, if in the opinion of the investigator the dose of the drug is sufficiently low to not represent a significant anti-cholinergic burden, then the subject can be included in the study
- •11. Ongoing episode of major depression, or current diagnosis or history of schizophrenia, bipolar disorder or any other psychiatric condition which could significantly interfere with their cooperation in participating in the study
- •12. Significant neurological or medical disorders that in the opinion of the investigator may impair cognitive performance such as epilepsy, Parkinson’s disease, clinical episode of stroke/TIA. In these instances, consensus agreement with the sponsor regarding participant eligibility should be sought
- •13. History of malignancy of any organ treated within the past 2 years, regardless of whether there is evidence of local recurrence or metastases. However localised basal cell carcinoma or localised squamous cell of the skin are permitted
- •14. Prior history of prostate cancer or:
- •> ULN for age-adjusted PSA values
- •Clinical suspicion of malignancy on digital rectal examination (DRE) o Except where the participants have been assessed by an urologist and all causes for high PSA/abnormal size on DRE other than Benign Prostatic Hyperplasia /Prostatitis have been ruled out
- •High risk of prostate cancer according to family history (men with one or more first-degree relatives diagnosed <65yo, or men with a first-degree relative with familial breast cancer (BRCA1 or BRCA2))
- •15. Personal or family history of thrombophilia, or personal history of deep vein thrombosis (DVT) / pulmonary embolism
研究者
相似试验
未知
2 期
Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With HypertensioHigh Blood PressureJPRN-jRCT2080222043ovartis Pharma K.K.432
进行中（未招募）
1 期
Effects of Dapagliflozin on CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD)MedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersChronic kidney diseaseEUCTR2021-000995-13-DKDepartment of Cardiology, Herlev and Gentofte hospital260
尚未招募
不适用
A clinical study to assess the Efficacy and Safety of SAW-1720 in Benign Prostate Hyperplasia patientsCTRI/2020/09/027521Akay Natural Ingredients Pvt Ltd
进行中（未招募）
不适用
A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate /Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets versus Fenofibrate or Simvastatin Monotherapies in Subjects with Abnormal Levels of Fats(lipids) in the Blood and at High Risk of Cardiovascular Disease.MedDRA version: 15.1Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861DyslipidemiaEUCTR2011-005924-16-PLAbbott Laboratories Ireland Limited600
进行中（未招募）
不适用
A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate /Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets versus Fenofibrate or Simvastatin Monotherapies in Subjects with Abnormal Levels of Fats(lipids) in the Blood and at High Risk of Cardiovascular Disease.DyslipidemiaMedDRA version: 14.1Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2011-005924-16-CZAbbott Laboratories Ireland Limited600